U. S. health regulators FDA can approve the second drug to treat low sexual desire in women.
The drug name is bremelanotide would be marketed by Amag Pharmaceuticals Inc. under the brand name Vyleesi.
It comes in an auto-injecting pen that premenopausal women would take before 45 minutes before sex.
Addyi was the first female libido booster or female hypoactive sexual desire disorder drug approved by the FDA in 2015. This condition affects about 10% of all women.
Palatin Technologies Inc. developed this new drug, receive $300 million agreement that gives AMANG rights to sell it.
This could give wings to women experiencing sexual trouble. Marketers are not shy about suggesting these drugs.
Vyleesi is the first drug that is the investigation on the point of view women’s sexual desire or dysfunctioning.
FDA uses to determine the effectiveness of the drug, bremelanotide is promising. In the final round of clinical trial, 60% of subjects reported improvement over their low libido and distress level.
Women must take the drug daily at a cost of $426 per month. But FDA warned that the drug should not be taken within two hours of alcohol consumption.